Allegheny Health Network | Strategic Alliance Partners

March 08, 2024

Eirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.

March 08, 2024

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

March 08, 2024

Suzanne B. Coopey, MD, FACS, discusses ways that women in oncology can feel further supported and advocated for in the cancer care space.

March 08, 2024

Suzanne B. Coopey, MD, highlights the initial challenges that she experienced during her residency and expands on the support found in the field.

March 08, 2024

Suzanne B. Coopey, MD, FACS, discusses the importance of addressing gender disparities in cancer care.

February 02, 2024

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

January 24, 2024

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

January 24, 2024

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

January 23, 2024

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

January 10, 2024

Sarah Crafton, MD, discusses novel therapeutic targets under investigation in patients with ovarian cancer.

January 10, 2024

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

January 09, 2024

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

December 20, 2023

The Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

December 17, 2023

A phase 1/2 study will assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.

December 08, 2023

Allegheny Health Network Cancer Institute’s (AHNCI) Radiation Oncology program recently attained accreditation from the American Society for Radiation Oncology APEx - Accreditation Program for Excellence® for all 13 of its radiation oncology facilities.

December 07, 2023

State of the Science Summit - Gynecologic Cancers: Chaired by Thomas C. Krivak, MD and Eirwen M. Miller, MD

November 03, 2023

Allegheny Health Network Cancer Institute unveiled its new, state-of-the-art Skin Cancer Center at West Penn Hospital, featuring a first-in-the-region full-body 3D imaging system that provides custom digital surveillance for skin abnormalities.

September 19, 2023

Interventional Radiologists at Allegheny Health Network's West Penn Hospital are the first in the region, and among the first in the country, to use a cutting-edge new technology called the Aliya Pulsed Electrical Field system, to target and eradicate cancer cells while preserving healthy adjacent tissues.

August 01, 2023

More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.

June 29, 2023

Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.